Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Myelodysplastic Syndromes 13Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Leukemia, Myeloid, Acute 9Leukemia 8Hematologic Neoplasms 7Lymphoma, Non-Hodgkin 6Lymphoma 6Multiple Myeloma 4Primary Immunodeficiency Diseases 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Hodgkin Disease 3Cytopenia 3Anemia, Aplastic 3Thalassemia 2Osteopetrosis 2Neoplasm, Residual 2Neoplasm Metastasis 2Leukemia, Lymphocytic, Chronic, B-Cell 2Immunoproliferative Disorders 2Immune System Diseases 2Hemoglobinopathies 2Fanconi Anemia 2Cytokine Release Syndrome 2Breast Neoplasms 2Anemia, Sickle Cell 2Anemia, Diamond-Blackfan 2Anemia 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Thymoma 1

Interventions

AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castrate Resistant Prostate Cancer (CRPC) × AP 1903 reagent × Clear all
NCT00868595 2019-10-08

MTD Study of Vaccine BP-GMAX-CD1 Plus AP1903 to Treat Castrate Resistant Prostate Cancer

Bellicum Pharmaceuticals

Phase 1 Completed
18 enrolled
Genitourinary

Castrate Resistant Prostate Cancer (CRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡